BRIEF—Resolution appoints liver disease expert as CMO

Resolution Therapeutics, a UK biopharma company developing macrophage cell therapies to treat advanced liver disease, has appointed leading liver disease expert and clinical developer, Dr Clifford Brass, as chief medical officer (CMO).

“We are delighted to welcome Cliff to Resolution as chief medical officer,” said Dr Edward Hodgkin, chief executive of Resolution, adding: “He has a strong track record in liver disease, having designed and led multiple clinical development programs. Cliff’s experience and leadership will be invaluable as Resolution progresses its first liver-directed engineered macrophage cell therapy into the clinic.”

Most recently Dr Brass was vice president, head of clinical sciences for hepatology, gastroenterology and transplantation in global drug development at Novartis. Prior to that he worked at Schering-Plough/Merck and led medical affairs efforts in HCV before transitioning to lead multiple programs in drug development encompassing more than 30 NDAs/label changes in the USA, European Union and Japan.